127 filings
8-K
QLGN
Qualigen Therapeutics Inc
30 May 24
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
4:00pm
8-K
QLGN
Qualigen Therapeutics Inc
16 Apr 24
Entry into a Material Definitive Agreement
4:10pm
8-K
QLGN
Qualigen Therapeutics Inc
28 Mar 24
Termination of a Material Definitive Agreement
4:05pm
8-K
QLGN
Qualigen Therapeutics Inc
27 Feb 24
Entry into a Material Definitive Agreement
7:00am
8-K
QLGN
Qualigen Therapeutics Inc
22 Feb 24
Entry into a Material Definitive Agreement
4:10pm
8-K
ririva43pavaimcsuq
7 Dec 23
Entry into a Material Definitive Agreement
4:15pm
8-K
xtst jhw3
22 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
4y1fmiapb
14 Nov 23
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
5:10pm
8-K
s5s2bm
8 Nov 23
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
2:16pm
8-K
io3iyq bzrlowc2va1
17 Oct 23
Regulation FD Disclosure
8:30am
8-K
21rdifm3k59lwe2j7e
28 Sep 23
Entry into a Material Definitive Agreement
4:15pm
8-K
g49kwhgudmx fp8x
15 Aug 23
Results of Operations and Financial Condition
10:04am
8-K
wuq0c1nf
4 Aug 23
Departure of Directors or Certain Officers
4:30pm
8-K
dct pifw6dwxid7c1hs
1 Aug 23
Regulation FD Disclosure
8:35am
8-K
h9esh9ah1k 7r
26 Jul 23
Entry into a Material Definitive Agreement
5:25pm
8-K
cgpsski1
13 Jul 23
Submission of Matters to a Vote of Security Holders
5:29pm
8-K
wcixf fjpn1l
26 Jun 23
Departure of Directors or Certain Officers
5:25pm
8-K
wl8pnt6w t4
19 May 23
Departure of Directors or Certain Officers
8:20am
8-K
4mwbqyt4ywny qljz
5 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K
hrdcygg 9jmu
24 Apr 23
Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing
6:15am